Edition:
United Kingdom

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

18.11USD
25 Sep 2018
Change (% chg)

$0.42 (+2.37%)
Prev Close
$17.69
Open
$17.75
Day's High
$18.15
Day's Low
$17.63
Volume
342,960
Avg. Vol
360,281
52-wk High
$21.19
52-wk Low
$13.00

Chart for

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $2,604.40
Shares Outstanding(Mil.): 149.59
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.97 -- --
ROI: -23.24 1.79 14.61
ROE: -332.60 3.28 16.33

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

03 May 2018

BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies

* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS

01 May 2018

BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29

* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE

01 May 2018

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

09 Apr 2018

Earnings vs. Estimates